Chimerix
forward looking statements this presentation contains forward looking statements within the meaning of the private securities litigation reform act of that are subject to risks and uncertainties that could cause actual results to differ materially from those projected forward looking statements include those relating to among other things the probability of success of the phase action study the potential filing and approval of an for and subsequent commercial opportunity the implications of the radiographic partial response observed during dose the ability to reproduce clinical and clinical findings and projections regarding funding and timing of future data among the factors and risks that could cause actual results to differ materially from those indicated in the forward looking statements are risks related to the timing completion and outcome of the phase action study of risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies risks related to the clinical development of and additional risks set forth in the company filings with the securities and exchange commission these forward looking statements represent the company judgment as of the date of this release the company disclaims however any intent or obligation to update these forward looking statements | Chimerix
Company
Deck date
May 2023
Slide
2 of 41
Similar slides by Chimerix
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Related slides by other companies
Results
August 2023
Results
August 2022
Investor Conference
January 2024
Results
November 2015
Other recent decks by Chimerix
Investor Presentation
August 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io